Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442501 in Achondroplasia (Pediatric, China)
CTR20233140Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2023
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SAR442501 in achondroplasia (ACH), sponsored by Sanofi. Started Oct 2023; status: terminated.
02
Drugs
SAR442501
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on CTR20233140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233140.